PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study

Inclusion Criteria

• •Patients with the diagnosis of neuroblastoma must meet both of the following criteria:
• •* Diagnosis confirmed by histological assessment by MSKCC Department of pathology or by the presence of BM metastases PLUS elevated urinary catecholamines
• •* Relapsed or refractory stage 4 disease or relapsed or refractory stage MYCN-amplified 2B or 3 disease.
• •* Patients with tumors other than neuroblastoma must meet both the following criteria:
• •* Have one of the following diagnoses (these tumors are known to express GD2 on cell surface):
• •* Melanoma
• •* Osteogenic sarcoma
• •* Leiomyosarcoma
• •* Ewing sarcoma
• •* Liposarcoma
• •* Fibrosarcoma
• •* Malignant fibrous histiocytoma
• •* Spindle cell sarcoma
• •* Small cell lung cancer
• •* Medulloblastoma metastatic to extracranial sites
• •* Paraganglioma
• •* Have refractory or relapsed or metastatic disease
• •* Immunohistochemical demonstration of GD2 expression on cell surface (Tumor assessment by immunohistochemistry is required for this group of patients)
• •* Have refractory or relapsed disease or metastatic disease. All patients must have measurable or evaluable disease
• •* Age 3-90 years
• •* Prior treatment with anti-GD2 monoclonal antibody is permitted only if human anti-human antibody titer is ≤1300 assay developed by Dr. Nai-Kong Cheung.
• •* Negative serum pregnancy test in women of childbearing potential
• •* Women of child-bearing potential must be willing to practice an effective method of birth control while on study
• •* Signed informed consent indicating awareness of the investigational nature of this study.